Novo Nordisk bids $9bn for obesity drug maker Metsera in challenge to Pfizer
诺和诺德出价90亿美元收购肥胖药制造商Metsera，以挑战辉瑞
Novo Nordisk, which owns Ozempic and Wegovy, was accused by Pfizer of making a ‘reckless’ offer.
2025-10-30 469词 简单
Pfizer criticised the unsolicited bid, accusing Novo Nordisk of making a “reckless” offer and claiming it was “an attempt by a company with a dominant market position to suppress competition in violation of law by taking over an emerging American challenger”.
免责声明：本文来自网络公开资料，仅供学习交流，其观点和倾向不代表本站立场。